Viewing data from:

PENTASA

NDA

MESALAMINE | N020049 | TAKEDA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Pentasa (2023)

Total Spending

$34.4M

Total Claims

25,067

Beneficiaries

5,815

Avg Cost/Unit

$5.26

Spending Trend

$86.4M(2019)→$83.5M(2020)→$77.2M(2021)→$52.1M(2022)→$34.4M(2023)

YoY Change:-5.4%

5yr CAGR:-1.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain24 active DMFs12 inactive

21 active API suppliers hold Drug Master Files for this ingredient.

CORDEN PHARMA BERGAMO SPAMESALAMINE

DMF 118071996

CHEMI SPAMESALAMINE USP

DMF 119511996

ERREGIERRE SPAMESALAMINE USP-EP

DMF 138831998

SYNTESE ASMESALAMINE (5-AMINOSALICYLIC ACID) DRUG SUBSTANCE

DMF 196182006

IPCA LABORATORIES LTDMESALAMINE USP (PROCESS II)

DMF 226172010

ZYDUS LIFESCIENCES LTDMESALAMINE USP

DMF 229992009

ALP PHARM BEIJING CO LTDMESALAMINE

DMF 242562010

ERREGIERRE SPAMESALAMINE USP - PH.EUR. (HIGH DENSITY)

DMF 248892011

CHEMI SPAMESALAMINE CRYSTALLIZED, USP

DMF 253852011

ZYDUS LIFESCIENCES LTDMESALAMINE USP (PROCESS-II)

DMF 279392014

CTX LIFE SCIENCES PVT LTDMESALAMINE USP

DMF 290512015

SUN PHARMACEUTICAL INDUSTRIES LTDMESALAMINE USP

DMF 295752015

DIVIS LABORATORIES LTDMESALAMINE USP

DMF 299982015

MAITHRI DRUGS PRIVATE LTDMESALAMINE USP

DMF 315702017

APITORIA PHARMA PRIVATE LTDMESALAMINE USP

DMF 339102019

ALKEM LABORATORIES LTDMESALAMINE USP

DMF 339392019

MATRIX PHARMACORP PRIVATE LTDMESALAMINE USP

DMF 343742019

AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD)MESALAMINE

DMF 347922020

OPTIMUS DRUGS PRIVATE LTDMESALAMINE

DMF 351362020

SOLARA ACTIVE PHARMA SCIENCES LTDMESALAMINE USP

DMF 357172021

ZHEJIANG HENGKANG PHARMACEUTICAL CO LTDMESALAMINE USP

DMF 373192022

DASAMI LAB PRIVATE LTDMESALAMINE USP

DMF 374132022

IOL CHEMICALS AND PHARMACEUTICALS LTDMESALAMINE USP

DMF 383382023

MSN LIFE SCIENCES PRIVATE LTDMESALAMINE USP

DMF 396702024

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveMESALAMINE USP (5-AMINO SALICYLIC ACID)

DMF 164312003

SIMS SRLInactiveMESALAMINE

DMF 180542005

DR REDDYS LABORATORIES LTDInactiveMESALAMINE

DMF 183872005

IPCA LABORATORIES LTDInactiveMESALAMINE USP

DMF 192612006

CORDEN PHARMA BERGAMO SPAInactiveMESALAMINE HIGH DENSITY

DMF 199932006

LUPIN MANUFACTURING SOLUTIONS LTDInactiveMESALAMINE USP

DMF 214892008

LUPIN LTDInactiveMESALAMINE USP

DMF 215142008

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveMESALAMINE USP

DMF 246642011

IPCA LABORATORIES LTDInactiveMESALAMINE USP (MZ3 PROCESS)

DMF 272452013

SIGNA SA DE CVInactiveMESALAMINE USP

DMF 296762016

WANBURY LTDInactiveMESALAMINE

DMF 318872017

BEC CHEMICALS PRIVATE LTDInactiveMESALAMINE USP

DMF 362572023

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

18 letters from Drugs@FDA

Date	Submission	Document
Jul 31, 2024	SUPPL -41	View Letter (PDF)
Oct 25, 2023	SUPPL -40	View Letter (PDF)
Nov 17, 2022	SUPPL -38	View Letter (PDF)
Nov 2, 2021	SUPPL -36	View Letter (PDF)
May 26, 2021	SUPPL -35	View Letter (PDF)
Nov 2, 2020	SUPPL -34	View Letter (PDF)
Oct 2, 2020	SUPPL -33	View Letter (PDF)
Jul 17, 2019	SUPPL -32	View Letter (PDF)
May 31, 2018	SUPPL -31	View Letter (PDF)
Aug 25, 2017	SUPPL -28	View Letter (PDF)
Jul 28, 2017	SUPPL -30	View Letter (PDF)
Aug 10, 2015	SUPPL -27	View Letter (PDF)
Dec 17, 2013	SUPPL -26	View Letter (PDF)
Jul 26, 2013	SUPPL -25	View Letter (PDF)
Jul 5, 2007	SUPPL -19	View Letter (PDF)
Jul 3, 2006	SUPPL -17	View Letter (PDF)
Jul 14, 2004	SUPPL -15	View Letter (PDF)
Sep 10, 1999	SUPPL -6	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 250MG

RLDAB

0 patents0 exclusivities▴

CAPSULE, EXTENDED RELEASE;ORAL | Approved: May 10, 1993

No patent or exclusivity listings for this strength.

#002 — 500MG

RLDAB

0 patents0 exclusivities▾

CAPSULE, EXTENDED RELEASE;ORAL | Approved: Jul 8, 2004